Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

The vaccine made by Moderna Inc. is to be approved later ... Japan’s mistrust of vaccines is decades old, partly because side effects have often been played up. In the 1990s, the government ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

A growing number of UK women are reporting a dramatic increase in breast size following COVID-19 vaccination, with some ...

Even so, broadening the range of trials’ participants can be practically useful, because they may lead to new medical ...

And regular polling carried out by YouGov suggests adults are increasingly likely to say that vaccines have harmful side ...

Maplebear Inc (CART) closed up more than +4% after S&P Dow Jones Indices said the stock will be added to the S&P Midcap 400 Index before the start of trading on Tuesday, January 14.  Allstate (ALL) ...

Art Chansky ruminates on a new idea from Mike Krzyzewski: merging the Big East and ACC into one super-conference.

Kashmir's leading scientist and gastroenterologist, Prof M Sultran Khuroo writes about the evolution of the Human ...

The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect against bird flu, the pharmaceutical company announced Friday.

Earlier this month, Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s lackluster vaccine sales in COVID-19 and respiratory ...

Moderna projects $1.5 billion-$2.5 billion in 2025 revenue, with cash and investments estimated at $6 billion by year-end. 2024 product sales are approximately $3 billion-$3.1 billion, driven by $ ...